Učitavanje...
SET and MYND domain-containing protein 3 inhibits tumor cell sensitivity to cisplatin
Cisplatin resistance has been a major factor limiting its clinical use as a chemotherapy drug. The present study aimed to investigate whether SET and MYND domain-containing protein 3 (SMYD3), a histone methyltransferase closely associated with tumors can affect the sensitivity of tumors to cisplatin...
Spremljeno u:
| Izdano u: | Oncol Lett |
|---|---|
| Glavni autori: | , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
D.A. Spandidos
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7114722/ https://ncbi.nlm.nih.gov/pubmed/32269620 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2020.11465 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|